Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

ABSTRACT:

Background

In the GeparX trial (NCT02682693), neoadjuvant denosumab, in addition to either weekly or days 1 and 8 (d1,8) q22 nab-paclitaxel (nPac)-based chemotherapy, did not improve the pathological complete response (pCR) rate in early high-risk breast cancer patients, while the concomitantly applied weekly nPac regimen resulted in a significantly higher pCR rate compared with the interrupted regimen.

Patients and methods

GeparX is a randomized, open-label, phase II study comparing neoadjuvant treatment with or without denosumab and two different nPac schedules. Invasive disease-free survival (iDFS), distant disease-free survival (DDFS), overall survival (OS), and locoregional recurrence-free interval (LRRFI) were considered as time-to-event endpoints.

Results

After

SUBMITTER: Link T 

PROVIDER: S-EPMC12702335 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature